Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies

Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan

Research output: Contribution to journalReview article

Abstract

Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell–active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.

Original languageEnglish
Pages (from-to)511-519
Number of pages9
JournalClinics in Liver Disease
Volume23
Issue number3
DOIs
Publication statusPublished - 1 Aug 2019

Fingerprint

Hepatitis B
Neoplasms
Drug Therapy
Immunosuppressive Agents
Immunosuppression
Antiviral Agents
Therapeutics

Cite this

Sasadeusz, Joe ; Grigg, Andrew ; Hughes, Peter D. ; Lim, Seng Lee ; Lucas, Michaela ; McColl, Geoff ; McLachlan, Sue Anne ; Peters, Marion G. ; Shackel, Nicholas ; Slavin, Monica ; Sundararajan, Vijaya ; Thompson, Alexander ; Doyle, Joseph ; Rickard, James ; De Cruz, Peter ; Gish, Robert G. ; Visvanathan, Kumar. / Screening and Prophylaxis to Prevent Hepatitis B Reactivation : Patients with Hematological and Solid Tumor Malignancies. In: Clinics in Liver Disease. 2019 ; Vol. 23, No. 3. pp. 511-519.
@article{f0abacdd6ce64b9d9caff308fb4d05cf,
title = "Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies",
abstract = "Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell–active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.",
keywords = "Cancer, Hematological malignancy, Hepatitis B, Prophylaxis, Reactivation, Rituximab, Solid tumors",
author = "Joe Sasadeusz and Andrew Grigg and Hughes, {Peter D.} and Lim, {Seng Lee} and Michaela Lucas and Geoff McColl and McLachlan, {Sue Anne} and Peters, {Marion G.} and Nicholas Shackel and Monica Slavin and Vijaya Sundararajan and Alexander Thompson and Joseph Doyle and James Rickard and {De Cruz}, Peter and Gish, {Robert G.} and Kumar Visvanathan",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.cld.2019.04.011",
language = "English",
volume = "23",
pages = "511--519",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Sasadeusz, J, Grigg, A, Hughes, PD, Lim, SL, Lucas, M, McColl, G, McLachlan, SA, Peters, MG, Shackel, N, Slavin, M, Sundararajan, V, Thompson, A, Doyle, J, Rickard, J, De Cruz, P, Gish, RG & Visvanathan, K 2019, 'Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies' Clinics in Liver Disease, vol. 23, no. 3, pp. 511-519. https://doi.org/10.1016/j.cld.2019.04.011

Screening and Prophylaxis to Prevent Hepatitis B Reactivation : Patients with Hematological and Solid Tumor Malignancies. / Sasadeusz, Joe; Grigg, Andrew; Hughes, Peter D.; Lim, Seng Lee; Lucas, Michaela; McColl, Geoff; McLachlan, Sue Anne; Peters, Marion G.; Shackel, Nicholas; Slavin, Monica; Sundararajan, Vijaya; Thompson, Alexander; Doyle, Joseph; Rickard, James; De Cruz, Peter; Gish, Robert G.; Visvanathan, Kumar.

In: Clinics in Liver Disease, Vol. 23, No. 3, 01.08.2019, p. 511-519.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Screening and Prophylaxis to Prevent Hepatitis B Reactivation

T2 - Patients with Hematological and Solid Tumor Malignancies

AU - Sasadeusz, Joe

AU - Grigg, Andrew

AU - Hughes, Peter D.

AU - Lim, Seng Lee

AU - Lucas, Michaela

AU - McColl, Geoff

AU - McLachlan, Sue Anne

AU - Peters, Marion G.

AU - Shackel, Nicholas

AU - Slavin, Monica

AU - Sundararajan, Vijaya

AU - Thompson, Alexander

AU - Doyle, Joseph

AU - Rickard, James

AU - De Cruz, Peter

AU - Gish, Robert G.

AU - Visvanathan, Kumar

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell–active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.

AB - Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell–active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.

KW - Cancer

KW - Hematological malignancy

KW - Hepatitis B

KW - Prophylaxis

KW - Reactivation

KW - Rituximab

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=85066787931&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2019.04.011

DO - 10.1016/j.cld.2019.04.011

M3 - Review article

VL - 23

SP - 511

EP - 519

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -